Germline Susceptibility to Treatment Toxicity in Cancer (Animal/Cell Studies)
A study explored treatment toxicity profiles in cancer therapies, identifying variations based on cancer type and treatment. It highlighted two modes of genetic susceptibility: one related to organ function affecting various treatments, and another involving immune responses specifically during immunotherapy. Notably, a genetic variant (HLA-DRB1*15) was linked to adrenal insufficiency and multiple sclerosis. This was based on analysis of adverse events such as pneumonitis and hypothyroidism.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
Understanding these genetic susceptibilities is crucial for improving patient safety and tailoring oncological treatments. While it provides insights into how certain genetic factors may influence treatment toxicity, it does not establish a direct cause-and-effect relationship between these factors and the observed side effects.
What this does not prove
The study does not establish causality between the identified genetic determinants and systemic therapy toxicity.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- No
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-17
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidencePopulation-Scale Precision Safety in Oncology Reveals Clinical and Genetic Determinants of Systemic Therapy Toxicity. ↗DOI: 10.64898/2026.09.16.26363259
Supporting passages (7)
sample size basisBeyond clinical predictors, we identified two modes of germline susceptibility to treatment toxicity: an organ-intrinsic mode, in which germline variation confers risk across systemic therapies, exemplified by a regulatory variant near FOXE1 associated with hypothyroidism; and an immune-mediated mode, confined to immune checkpoint inhibitor-treated patients, in which HLA-DRB1*15 was a major determinant of adrenal insufficiency.
randomizedNo
peer reviewedNo
publication date2026-09-17
interventionanti-cancer therapy
findingsAnalysis of six representative adverse events-pneumonitis, adrenal insufficiency, liver toxicity, colitis, hyperthyroidism and hypothyroidism-revealed distinct toxicity landscapes shaped by cancer type, treatment regimen, and clinical context.
limitationsTitle: Population-Scale Precision Safety in Oncology Reveals Clinical and Genetic Determinants of Systemic Therapy Toxicity.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.